Basics BridgeBio Pharma, Inc. IPO Date: June 24, 2019 Sector: Healthcare Industry: Biotech Market Cap: $14.19B Activated in VL: True Average Daily Range Avg Daily Range: $0.85 | 3.03% Avg Daily Range (30 D): $1.34 | 2.08% Avg Daily Range (90 D): $1.08 | 1.94% Institutional Daily Volume Avg Daily Volume: 1.46M Avg Daily Volume (30 D): 2.2M Avg Daily Volume (90 D): 2.07M Trade Size Avg Trade Size (Sh.): 83 Avg Trade Size (Sh.) (30 D): 62 Avg Trade Size (Sh.) (90 D): 64 Institutional Trades Total Inst.Trades: 7,124 Avg Inst. Trade: $3.1M Avg Inst. Trade (30 D): $4.49M Avg Inst. Trade (90 D): $4.38M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 4 Market Closing Trades Avg Closing Trade: $7.09M Avg Closing Trade (30 D): $18.51M Avg Closing Trade (90 D): $16.84M Avg Closing Volume: 246.75K     News Nov 8, 2025 @ 3:41 PM Acoramidis Significantly Reduces All-cause Mortali... Source: Bridgebio Pharma Nov 7, 2025 @ 6:00 PM National Advertising Division Will Refer BridgeBio... Source: Globe Newswire Oct 27, 2025 @ 11:00 AM BridgeBio Reports Positive Phase 3 Results for Sma... Source: Bridgebio Pharma, Inc. Sep 28, 2025 @ 3:15 PM Acoramidis Begins to Reduce Cumulative Cardiovascu... Source: Bridgebio Pharma Sep 6, 2025 @ 6:30 PM Encaleret Showed Parathyroid Hormone-Independent N... Source: Bridgebio Pharma, Inc. Financials   TTM Q2 2025 Q1 2025 Basic EPS $-4.11 $-.95 $-.88 Diluted EPS $-4.11 $-.95 $-.88 Revenue $ 235.81M $ 110.57M $ 116.63M Gross Profit $ 226.84M $ 106.91M $ 113.99M Net Income / Loss $ -785.01M $ -183.76M $ -169.61M Operating Income / Loss $ -656.43M $ -134.28M $ -104.37M Cost of Revenue $ 8.97M $ 3.65M $ 2.64M Net Cash Flow $ 201.59M $ 208.36M $ -140.5M PE Ratio